Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: MINIVELLE

« Back to Dashboard
Minivelle is a drug marketed by Noven and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and seventy-two patent family members in twenty-nine countries.

The generic ingredient in MINIVELLE is estradiol. There are seventy-four drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the estradiol profile page.

Summary for Tradename: MINIVELLE

Suppliers / Packagers: see list5

Pharmacology for Tradename: MINIVELLE

Ingredient-typeEstradiol Congeners
Drug ClassEstrogen
Mechanism of ActionEstrogen Receptor Agonists

Clinical Trials for: MINIVELLE

Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
Status: Active, not recruiting Condition: Atrophic Vaginitis; Breast Cancer

Postpartum Depression: Transdermal Estradiol Versus Sertraline
Status: Terminated Condition: Postpartum Depression

Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms
Status: Completed Condition: Hot Flashes

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients
Status: Completed Condition: Sexual Dysfunction, Physiological

Duragen Versus Duraguard in Chiari Surgery
Status: Completed Condition: Chiari Malformation

Perimenopausal Effects of Estradiol on Reward Responsiveness
Status: Not yet recruiting Condition: Perimenopausal Depression

A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC
Status: Completed Condition: Contraception; Bleeding

Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone
Status: Completed Condition: Pharmacokinetics of Isavuconazole; Pharmacokinetics of Ethinyl Estradiol and Norethindrone; Healthy Volunteers

Vaginal Estradiol Pretreatment in Labour Induction With Misoprostol
Status: Recruiting Condition: Failed Induction of Labor

Efficacy and Safety Of Spil's Estradiol Vaginal Tablet
Status: Terminated Condition: Vulvar Atrophy; Vaginal Atrophy

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
FILM, EXTENDED RELEASE;TRANSDERMAL203752-005Sep 23, 2014RXNo8,231,906<disabled>YY <disabled>
FILM, EXTENDED RELEASE;TRANSDERMAL203752-003Oct 29, 2012RXNo6,841,716<disabled>Y <disabled>
FILM, EXTENDED RELEASE;TRANSDERMAL203752-001Oct 29, 2012RXNo8,231,906<disabled>YY <disabled>
FILM, EXTENDED RELEASE;TRANSDERMAL203752-004Oct 29, 2012RXYes8,231,906<disabled>YY <disabled>
FILM, EXTENDED RELEASE;TRANSDERMAL203752-003Oct 29, 2012RXNo5,656,286<disabled>YY <disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MINIVELLE

Drugname Dosage Strength RLD Submissiondate
estradiolTransdermal System0.025 mg/dayMinivelle5/8/2015
estradiolTransdermal System0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, 0.1 mg/dayMinivelle8/18/2014

Non-Orange Book Patents for Tradename: MINIVELLE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,719,197 Compositions and methods for topical administration of pharmaceutically active agents<disabled in preview>
5,686,099 Method and device for the release of drugs to the skin<disabled in preview>
6,024,976 Solubility parameter based drug delivery system and method for altering drug saturation concentration<disabled in preview>
6,221,383 Solubility parameter based drug delivery system and method for altering drug saturation concentration<disabled in preview>
4,814,168 Transdermal multipolymer drug delivery system<disabled in preview>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MINIVELLE

Country Document Number Publication Date
Denmark0591432Jan 06, 2003
Japan4339398Oct 07, 2009
Norway307363Mar 27, 2000
European Patent Office0573576Jul 09, 2003
JapanH04504515Aug 13, 1992
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn